"Omron Healthcare did an excellent job of developing DPNCheck's
scientific and clinical credibility among leading academic and
practicing physicians in Japan," said
"We appreciate the important role of DPNCheck in early detection of
diabetic peripheral neuropathy and the avoidance or management of
related health complications," said Hiroyuki Babasaki, Senior Operating
Officer of Fukuda Denshi. "This unique technology has the potential to
meet the needs of medical facilities in
NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. For product information visit DPNCheck.com.
About Fukuda Denshi
Fukuda Denshi, headquartered in
NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.
Chief Financial Officer
News Provided by Acquire Media